Selective neuronal nitric oxide synthase inhibitors and the prevention of cerebral palsy

Annals of Neurology

Volumn 65, Issue 2, 2009, Pages 209-217

  Ji, Haitao ^a   Tan, Sidhartha ^b   Igarashi, Jotaro ^c,g   Huiying, Li ^c   Derrick, Matthew ^b   Martásek, Pavel ^d,e   Roman, Linda J ^d   Vasquez Vivar, Jeannette ^f   Poulos, Thomas L ^c   Silverman, Richard B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e CHARLES UNIVERSITY   (Czech Republic)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

^g TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ISOENZYME; NITRIC OXIDE SYNTHASE INHIBITOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; CEREBRAL PALSY; COGNITION; COMPUTER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEATH; DRUG DESIGN; ENZYME INHIBITION; EXPERIMENTAL MODEL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANIMALS, NEWBORN; ARGININE; BEHAVIOR, ANIMAL; BLOOD PRESSURE; BRAIN; CEREBRAL PALSY; CITRULLINE; CRYSTALLOGRAPHY, X-RAY; DISEASE MODELS, ANIMAL; DRUG DESIGN; ENZYME INHIBITORS; FEMALE; MALE; NEUROPROTECTIVE AGENTS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; PREGNANCY; RABBITS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 62549102043     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21555     Document Type: Article

References (46)

1. Lorenz JM. The outcome of extreme prematurity. Semin Peri-natol 2001;25:348-359.
2. Koinan LA, Smith, BP, Shilt JS. Cerebral palsy. Lancet 2004; 363:1619-1631.
3. Winter S, Autry A, Boyle C, Yeargin-AUsopp M. Trends in the prevalence of cerebral palsy in a population-based study. Pediatrics 2002;110:1220-1225.
4. Tyson JE, Gilstrap LC. Hope tor perinatal prevention of cerebral palsy. JAMA 2003;290:2730-2732.
5. O'Shea TM. Cerebral palsy in very preterm infants: new epidemiological insights. Ment Retard Dev Disabil Res Rev 2002; 8:135.....145.
6. Cowan F, Rutherford M, Groenendaal F, et al. Origin and timing of brain lesions in term infants with neonatal encephalopathy. Lancet 2003;361:736-742.
7. Robertson C, Finer N. Term infants with hypoxic-ischemic encephalopathy: outcome at 3.5 years. Dev Med Child Neurol 1985;27:473-484.
8. Ferriero DM, Holtzman DM, Black SM, Sheldon RA. Neonatal mice lacking neuronal nitric oxide synthase are less vulnerable to hypoxic-ischemic injury. Neurobiol Dis 1996;3:64-71.
9. Ferriero DM, Sheldon RA, Black SM, Chuai J. Selective destruction of nitric oxide synthase neurons with quisqualate reduces damage alter hypoxia-ischemia in the neonatal rat. Pediatr Res 1995;38:912-918.
10. Iadecola C, Zhang F, Casey R, et al. Delayed reduction ol ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J Neurosci 1997; 17: 9157-9164.
11. van den Tweel ERW, Nijboer C, Kavelaars A, et al. Expression of nitric oxide synthase isoforms and nitrotyrosine formation alter hypoxia-ischemia in the neonatal rat brain. J Neuroimmu-nol 2005;167:64-71.
12. Huang Z, Huang PL, Ma J, et al. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J Cereb Blood Flow Metab 1996;16:981-987.
13. G-nifro-L-argimne methyl ester (L-NAME) treatment is similar in immature and adult Wistar rats. Clin Sci 2003;105:483-489.
14. Wei X-q, Charles IG, Smith A, et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 1995; 375:408.....411.
15. Cho S, Park EM, Zhou P. et al. Obligatory role of inducible nitric oxide synthase in ischemic preconditioning. J Cereb Blood Flow Metab 2005;25:493-501.
16. Derrick M, Luo NL, Bregman JC, et al. Preterm fetal hypoxia-ischemia causes hypertonia and motor deficits in the neonatal rabbit: a model lor human cerebral palsy? J Neurosci 2004;24:24 -34.
17. Tan S, Drobyshevsky A, Jilling T, et al. Model of cerebral palsy in the perinatal rabbit. J Child Neurol 2005;20:972-979.
18. Erdal EP, Litzinger EA, Jinwon S, et al. Selective neuronal nitric oxide synthase inhibitors. Curr Top Med Cheui 2005;5: 603.....624.
19. Tafi A, Angli L, Venturini G, et al. Computational studies of competitive inhibitors of nitric oxide synthase (NOS) enzymes: towards the development of powerful and isoform-selective inhibitors. Curr Med Chem 2006;13:1929-1946.
20. G nitroarginine. Biochemistry 1993:32:8512-8517.
21. G-nitro-L- arginine. Br J Pharmacol 1996;118:1433-1440.
22. Hah J-M, Martásek P, Roman LJ, Silverman RB. Aromatic reduced amide and peptidomimetics as selective inhibitors of neuronal nitric oxide synthase. J Med Chem 2003;46:1661-1669.
23. Gomez-Vidal JA, Martásek P, Roman LJ, Silverman RB. Potent and selective conformationally restricted neuronal nitric oxide synthase inhibitors. J Med Chem 2004;47:703-710.
24. Flinspach ML, Li H, Jamal J, et al. Structural basis for dipep-tide amide isoform-selective inhibition of neuronal nitric oxide synthase. Nat Struct Mol Biol 2004;11:54-59.
25. Ji H, Li H, Flinspach M, et al. Computer modeling of selective regions in the active site of nitric oxide synthases: implication for the design of isoform-selective inhibitors. J Med Chem 2003;46:5700-5711.
26. Ji H, Stanton BZ, Igarashi J, et al. Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors. J Am Chem Soc 2008; 130:3900-3914.
27. Hajduk PJ, Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Disc 2007;6:211-219.
28. Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sura of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 2000;43:3714-3717.
29. Flinspach M, Li H, Jamal J, et al. Structures of the neuronal and endothelial nitric oxide synthase heme domain with D-nitroarginine-containing dipeptide inhibitors bound. Biochemistry 2004;43:5181-5187.
30. Li H, Flinspach ML, Igarashi J, et al. Exploring the binding conformations of bulkier dipeptide amide inhibitors in constitutive nitric oxide synthases. Biochemistry 2005;44: 15222-15229.
31. Jones TA, Zon J-Y, Cowan SW, Kjeldgaarrd M, Improved merhods for building models in electron density and rhe location of errors in these models. Acta Crystallogr 1991;A47: 110-119.
32. Brunger AT, Adams PD, Clore GM, er al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr 1998;D54:905 921.
33. Li H, Poulos TL. Structure-function studies on nitric oxide synthases. J Inorg Biochem 2005;99:293-305.
34. Norinder LJ, Haeberlein M. Computational approaches to the prediction of the blood-brain distribution. Adv Drug Deliv Rev 2002;54:291-313.
35. Miranker A, Karplus M. Functionality maps of binding sites: a multiple copy simultaneous search method. Proteins 1991;11: 29 -34.
36. Goodlord PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 1985;28:849-857.
37. Bohm H-J. The computer program LUD1: a new method for the de novo design of enzyme inhibitors. J Comput Aided Mol Des 1992;6:61-78.
38. Morris GM, Goodsell DS, Halliday RS, er al. Automated docking using a Lamarckian genetic algoridim and an empirical binding free energy function. J Comp Chem 1998; 19: 1639-1662.
39. van de Waterbeemd H, Smith DA, Beaumont K, Walker DK. Property-based design: optimization of drug absorption and pharmacokinetics. J Med Chem 2001;44:1313-1333.
40. Paudler WW, Blewitr HL. Ten α electron nitrogen heterocyclic compounds. V. The sire of protonation and N-merhylation of iraidazo[ 1,2-a]pyridines and the planarity of rhe ring sysrem. J Org Chem 1966;31:1295-1298.
41. Midler K, Faeh C, Diederich F. Fluorine in pharmaceuticals: looking beyond intuition. Science 2007;317:1881-1886.
42. Ishida A, Trescher WH, Lange MS, Johnston MV. Prolonged supression of brain nitric oxide synthase activity by 7-nitroindazole protects against cerebral hypoxic-ischemic injury in neonatal rat. Brain Dev 2001;23:349-354.
43. Vasquez-Vivar J, Hogg N, Martasek P, et al. Terrahydro-biopterin- dependent inhibition of superoxide generation from neuronal nitric oxide synthase. J Biol Chem 1999;274: 26736-26742.
44. Drobyshevsky A, Derrick M, Prasad PV, er al. Feral brain magnetic resonance imaging response acutely to hypoxia-ischemia predicts postnatal outcome. Ann Neurol 2007;61: 307-314.
45. Weiner SJ, Kollman PA, Case DA, et al. A new force field for molecular mechanical simulation of nucleic acid and proteins. J Am Chem Soc 1984;106:765-784.
46. Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity-a rapid access ro aromic charges. Terrahedron 1980;36:3219-3228.